Filing Details

Accession Number:
0001567619-22-001167
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-13 16:14:46
Reporting Period:
2022-01-11
Accepted Time:
2022-01-13 16:14:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1829802 Sensei Biotherapeutics Inc. SNSE Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1843594 James Peyer C/O Sensei Biotherapeutics, Inc.
1405 Research Blvd. Suite 125
Rockville MD 20850
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-11 10,845 $5.18 4,940,258 No 4 P Indirect See footnote
Common Stock Acquisiton 2022-01-12 9,202 $5.22 4,949,460 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
No 4 P Indirect See footnote
Footnotes
  1. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
  2. These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
  3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.20 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.